Why Exelixis Stock Leaped More Than 4% Higher Today
Although share repurchase programs have their detractors, investors tend to like when their companies announce them. This was the dynamic behind biotech stock Exelixis' (NASDAQ: EXEL) more than 4% rise in price on Monday; by contrast, the S&P 500 index rose by "only" 0.9%.
Before market open today, Exelixis announced that its board of directors has authorized new share buybacks. Up to $550 million has been allowed, in a program that will run until the end of this year.
As with most share repurchase programs, this one will see the biotech buy its own common stock from time to time, using a variety of methods. Exelixis also took pains to say that the arrangement does not obligate it to buy a particular amount of its shares, and that the initiative is subject to modification or suspension at any time.
Source Fool.com
